SP Group (SPG) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
30 Apr, 2026Executive summary
Achieved record Q1 2026 results with revenue up 22.9% year-over-year to DKK 966 million, driven by 11.3% organic growth and the Idé-Pro acquisition.
EBITDA margin reached 20.4% and EBT margin 13%, both at the upper end of guidance and historical highs.
Growth was broad-based across all product groups, with strong performance in proprietary products (+4.1%) and subcontracting/subsupplier projects (+30.5%).
Integration of Idé-Pro is progressing well, supporting cross-selling and capacity expansion, especially in India.
Expansion of healthcare production in Poland and operational launch of Stourup solar park.
Financial highlights
Revenue for Q1 2026 was DKK 966 million, up 22.9% from Q1 2025.
EBITDA grew 18.5% year-over-year to DKK 197 million (margin 20.4%).
EBT increased by 24.2% to DKK 125–126 million (margin 13.0%).
Diluted EPS up 28.4% to DKK 8.4; net profit DKK 99.2 million (+25.1%).
Operating cash flow improved to DKK 159 million, up DKK 28 million from last year; net interest-bearing debt reduced by DKK 72 million to DKK 1,388 million.
Outlook and guidance
Full-year 2026 guidance maintained: revenue growth of 15–23%, EBITDA margin of 19–21%, EBT margin of 11–13%.
Growth expected from new products, customers, and continued integration of Idé-Pro.
Guidance reflects caution due to ongoing geopolitical uncertainty, especially in the Middle East.
Latest events from SP Group
- Record revenue and profit growth in Q1 2026, with strong outlook and new share buy-back approved.SPG
Q1 202630 Apr 2026 - Record Q4 and Idé-Pro acquisition set stage for strong 2026 growth amid ongoing uncertainties.SPG
Q4 202525 Mar 2026 - Record Q4 and strong 2026 growth outlook, boosted by Idé-Pro acquisition.SPG
Q4 202525 Mar 2026 - Strong H1 2024 growth, upgraded outlook, and international expansion led by healthcare sales.SPG
Q2 202423 Jan 2026 - Record revenue and margin growth in 2024; cautious 2025 outlook with focus on own products.SPG
Q4 202426 Dec 2025 - Acquisition enables in-house toolmaking, new materials, and DKK 20–25m annual synergies.SPG
M&A Announcement19 Dec 2025 - Record Q1 growth and margin gains led by Healthcare; outlook steady amid global risks.SPG
Q1 202524 Nov 2025 - Q2 slowdown led to lower H1 results and a flat outlook, but margins and investments remain strong.SPG
Q2 202523 Nov 2025 - 2025 guidance maintained as order backlog and new projects offset lower sales and margins.SPG
Q3 202520 Nov 2025